Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Carl E. Orringer; Terry A. Jacobson; Joseph J. Saseen; Alan S. Brown; Antonio M. Gotto; Joyce L. Ross; James A. Underberg

doi:10.1016/j.jacl.2017.05.001

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Carl E. Orringer, Terry A. Jacobson, Joseph J. Saseen, Alan S. Brown, Antonio M. Gotto, Joyce L. Ross, James A. Underberg

Research output: Contribution to journal › Article › peer-review

88 Scopus citations

Abstract

An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol and have confirmed their excellent safety profile. A cardiovascular outcomes study has shown that these agents reduce incident atherosclerotic cardiovascular disease (ASCVD) events in patents with stable ASCVD and concomitant risk factors. The current update provides the Expert Panel's evidence-based recommendations on the clinical utility of PCSK9 inhibitors in patients with stable ASCVD, progressive ASCVD, LDL-C ≥ 190 mg/dL (including polygenic hypercholesterolemia, heterozygous familial hypercholesterolemia and the homozygous familial hypercholesterolemia phenotype) and very-high-risk patients with statin intolerance.

Original language	English (US)
Pages (from-to)	880-890
Number of pages	11
Journal	Journal of Clinical Lipidology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/j.jacl.2017.05.001
State	Published - Jul 2017

Keywords

Alirocumab
Dyslipidemia
Evolocumab
Familial hypercholesterolemia
Hypercholesterolemia
Lipid treatment guidelines
PCSK9 inhibitors
Statin intolerance

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacl.2017.05.001

Cite this

@article{1c552c93e2794b4098df1da2bd580b35,

title = "Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association",

abstract = "An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol and have confirmed their excellent safety profile. A cardiovascular outcomes study has shown that these agents reduce incident atherosclerotic cardiovascular disease (ASCVD) events in patents with stable ASCVD and concomitant risk factors. The current update provides the Expert Panel's evidence-based recommendations on the clinical utility of PCSK9 inhibitors in patients with stable ASCVD, progressive ASCVD, LDL-C ≥ 190 mg/dL (including polygenic hypercholesterolemia, heterozygous familial hypercholesterolemia and the homozygous familial hypercholesterolemia phenotype) and very-high-risk patients with statin intolerance.",

keywords = "Alirocumab, Dyslipidemia, Evolocumab, Familial hypercholesterolemia, Hypercholesterolemia, Lipid treatment guidelines, PCSK9 inhibitors, Statin intolerance",

author = "Orringer, {Carl E.} and Jacobson, {Terry A.} and Saseen, {Joseph J.} and Brown, {Alan S.} and Gotto, {Antonio M.} and Ross, {Joyce L.} and Underberg, {James A.}",

note = "Funding Information: C.E.O. has nothing to disclose. T.A.J. has received consulting fees from Amarin, Amgen, AstraZeneca, Merck and Co, and Sanofi Regeneron. J.J.S. has nothing to disclose. A.S.B. has received honoraria from Akcea, Amarin, Amgen, AstraZeneca, Merck and Co, Pfizer, Regeneron, and Sanofi. A.M.G. is on the Board of Directors with Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, and Esperion Therapeutics, a member of the Data Safety Monitoring Board for Ionis Pharmaceuticals, and received consulting fees from Kowa Pharmaceuticals, Merck and Co, Pfizer, and Vatera Capital. J.L.R. has received honoraria from AbbVie, Akcea, Amarin, Amgen, Kaneka America, Kastle Therapeutics, Kowa Pharmaceuticals, Practice Point, Regeneron, and Sanofi. J.A.U. received honoraria from Akcea, Alexion, Amarin, Amgen, Invitae, Sanofi, Regeneron, and True Health Diagnostics, consulting fees from Amarin and Amgen, and research grants from Aegerion and Sanofi. Publisher Copyright: {\textcopyright} 2017 National Lipid Association",

year = "2017",

month = jul,

doi = "10.1016/j.jacl.2017.05.001",

language = "English (US)",

volume = "11",

pages = "880--890",

journal = "Journal of Clinical Lipidology",

issn = "1933-2874",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Update on the use of PCSK9 inhibitors in adults

T2 - Recommendations from an Expert Panel of the National Lipid Association

AU - Orringer, Carl E.

AU - Jacobson, Terry A.

AU - Saseen, Joseph J.

AU - Brown, Alan S.

AU - Gotto, Antonio M.

AU - Ross, Joyce L.

AU - Underberg, James A.

N1 - Funding Information: C.E.O. has nothing to disclose. T.A.J. has received consulting fees from Amarin, Amgen, AstraZeneca, Merck and Co, and Sanofi Regeneron. J.J.S. has nothing to disclose. A.S.B. has received honoraria from Akcea, Amarin, Amgen, AstraZeneca, Merck and Co, Pfizer, Regeneron, and Sanofi. A.M.G. is on the Board of Directors with Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, and Esperion Therapeutics, a member of the Data Safety Monitoring Board for Ionis Pharmaceuticals, and received consulting fees from Kowa Pharmaceuticals, Merck and Co, Pfizer, and Vatera Capital. J.L.R. has received honoraria from AbbVie, Akcea, Amarin, Amgen, Kaneka America, Kastle Therapeutics, Kowa Pharmaceuticals, Practice Point, Regeneron, and Sanofi. J.A.U. received honoraria from Akcea, Alexion, Amarin, Amgen, Invitae, Sanofi, Regeneron, and True Health Diagnostics, consulting fees from Amarin and Amgen, and research grants from Aegerion and Sanofi. Publisher Copyright: © 2017 National Lipid Association

PY - 2017/7

Y1 - 2017/7

N2 - An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol and have confirmed their excellent safety profile. A cardiovascular outcomes study has shown that these agents reduce incident atherosclerotic cardiovascular disease (ASCVD) events in patents with stable ASCVD and concomitant risk factors. The current update provides the Expert Panel's evidence-based recommendations on the clinical utility of PCSK9 inhibitors in patients with stable ASCVD, progressive ASCVD, LDL-C ≥ 190 mg/dL (including polygenic hypercholesterolemia, heterozygous familial hypercholesterolemia and the homozygous familial hypercholesterolemia phenotype) and very-high-risk patients with statin intolerance.

AB - An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol and have confirmed their excellent safety profile. A cardiovascular outcomes study has shown that these agents reduce incident atherosclerotic cardiovascular disease (ASCVD) events in patents with stable ASCVD and concomitant risk factors. The current update provides the Expert Panel's evidence-based recommendations on the clinical utility of PCSK9 inhibitors in patients with stable ASCVD, progressive ASCVD, LDL-C ≥ 190 mg/dL (including polygenic hypercholesterolemia, heterozygous familial hypercholesterolemia and the homozygous familial hypercholesterolemia phenotype) and very-high-risk patients with statin intolerance.

KW - Alirocumab

KW - Dyslipidemia

KW - Evolocumab

KW - Familial hypercholesterolemia

KW - Hypercholesterolemia

KW - Lipid treatment guidelines

KW - PCSK9 inhibitors

KW - Statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=85019880943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019880943&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2017.05.001

DO - 10.1016/j.jacl.2017.05.001

M3 - Article

C2 - 28532784

AN - SCOPUS:85019880943

SN - 1933-2874

VL - 11

SP - 880

EP - 890

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

IS - 4

ER -

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this